Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond

被引:5
|
作者
Gu, Ruizhi [1 ]
Liang, Alina [2 ]
Liao, Grace [2 ]
To, Isabelle [2 ]
Shehu, Amina [1 ]
Ma, Xiaochao [1 ]
机构
[1] Univ Pittsburgh, Dept Pharmaceut Sci, Ctr Pharmacogenet, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA
基金
美国国家卫生研究院;
关键词
GLUTATHIONE-S-TRANSFERASE; ENDOTHELIAL GROWTH-FACTOR; PREGNANE X RECEPTOR; INDUCED HEPATOTOXICITY; ACETAMINOPHEN HEPATOTOXICITY; OXIDATIVE STRESS; GUT MICROBIOTA; RISK-FACTOR; MODULATES HEPATOTOXICITY; HEPATOCYTE REGENERATION;
D O I
10.1124/dmd.121.000457
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug-induced liver injury (DILI) remains one of the major concerns for healthcare providers and patients. Unfortunately, it is difficult to predict and prevent DILI in the clinic because detailed mechanisms of DILI are largely unknown. Many risk factors have been identified for both ???intrinsic??? and ???idiosyncratic??? DILI, suggesting that cofactors are an important aspect in understanding DILI. This review outlines the cofactors that potentiate DILI and categorizes them into two types: (1) the specific cofactors that target metabolic enzymes, transporters, antioxidation defense, immune response, and liver regeneration; and (2) the general cofactors that include inflammation, age, gender, comorbidity, gut microbiota, and lifestyle. The underlying mechanisms by which cofactors potentiate DILI are also discussed. SIGNIFICANCE STATEMENT This review summarizes the risk factors for DILI, which can be used to predict and prevent DILI in the clinic. This work also highlights the gaps in the DILI field and provides future perspectives on the roles of cofactors in DILI.
引用
收藏
页码:646 / 654
页数:9
相关论文
共 50 条
  • [31] Epidemiology of Idiosyncratic Drug-Induced Liver Injury
    Bell, Lauren N.
    Chalasani, Naga
    SEMINARS IN LIVER DISEASE, 2009, 29 (04) : 337 - 347
  • [32] Immunoallergic Drug-Induced Liver Injury in Humans
    Uetrecht, Jack
    SEMINARS IN LIVER DISEASE, 2009, 29 (04) : 383 - 392
  • [33] Drug-induced liver injury in the Australian setting
    Sistanizad, M.
    Peterson, G. M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (02) : 115 - 120
  • [34] Animal models of drug-induced liver injury
    McGill, Mitchell R.
    Jaeschke, Hartmut
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2019, 1865 (05): : 1031 - 1039
  • [35] Drug-Induced Liver Injury with Autoimmune Features
    deLemos, Andrew S.
    Foureau, David M.
    Jacobs, Carl
    Ahrens, Will
    Russo, Mark W.
    Bonkovsky, Herbert L.
    SEMINARS IN LIVER DISEASE, 2014, 34 (02) : 194 - 204
  • [36] Models of Idiosyncratic Drug-Induced Liver Injury
    Yokoi, Tsuyoshi
    Oda, Shingo
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021, 2021, 61 : 247 - 268
  • [37] Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury
    Sethi, Namya
    Khokhar, Manoj
    Mathur, Mitali
    Batra, Yashi
    Mohandas, Amal
    Tomo, Sojit
    Rao, Mahadev
    Banerjee, Mithu
    SEMINARS IN LIVER DISEASE, 2024, 44 (04) : 430 - 456
  • [38] Progress in the treatment of drug-induced liver injury with natural products
    Sun, Yuan-kai
    Zhang, Ya-fei
    Xie, Li
    Rong, Fan
    Zhu, Xing-yu
    Xie, Jing
    Zhou, Huan
    Xu, Tao
    PHARMACOLOGICAL RESEARCH, 2022, 183
  • [39] Tailored drug therapy for mitigating drug-induced liver injury: is this the era of genetic screening?
    Huang, Yi-Shin
    PERSONALIZED MEDICINE, 2010, 7 (01) : 5 - 8
  • [40] Alteration of mitochondrial DNA homeostasis in drug-induced liver injury
    Fromenty, Bernard
    FOOD AND CHEMICAL TOXICOLOGY, 2020, 135